Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jun 21, 2024 12:36pm
79 Views
Post# 36100213

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Bracelet

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Bracelet
NIce one Norm as this shows you too never bring anythng of value to the board. When did I ever say I should get more money than the execs of the board. Now you are straight out lying.
Just because someone does not say something everytime does not mean they approve otherwise you would contradict some on this board many times.
As I said, if i post something of a correction then it is always a quote from the pr or sedar doc  so how is that a lie unless you say that the documents or pr's are a lie. Oh and btw the last filing was not correct which states BT has poa.
And I am glad you are okay with the exec getting a raise but as long as they don't mislead shareholders like saying that for example we will have 2 phase 3 trials running in 2023.
Yes their position is never easy but don't mislead and don't be afraid to tell the truth or make the corrections.
Bottom line is we shall see just how forthcoming the end of the month is and where we stand and if we will partner or get bough out. I still believe they are in a blackout so negotiations of some sort must be going on as we know by not delcaring the Dec 2023 options they have been in a blackout for at least that long so hoping that this is a positive., And when they can actually show the shareholder value that they are always talking about then I will give them the credit that is due but until then the sp speaks for itself.
<< Previous
Bullboard Posts
Next >>